An observational study in ABO Hemolytic Disease of Newborn, sponsored by Women's Hospital School Of Medicine Zhejiang University. Recruiting at 1 site in China. Open to participants aged Up to 7 Days. Per ClinicalTrials.gov, last updated 2025-02-05.
Sponsored by Women's Hospital School Of Medicine Zhejiang University · Observational
A prospective observational cohort study was designed.
A prospective observational cohort study was designed. The participants included in the study are the neonates with hyperbilirubinemia in ABO incompatibility.Because the serological results are not known at the time of enrollment, all the neonates should be suspected hemolysis. According to the serological results,the neonates are divided into two groups, hemolytic group and non-hemolytic group. All the relevant clinical indicators need to be recorded and each neonates needs follow-up.
81 studies on the registry are indexed under Hyperbilirubinemia; 11 are open to participants now.
This study's planned enrollment of 112 is below the median of 450 across 25 observational studies indexed under Hyperbilirubinemia.
Browse Hyperbilirubinemia studies →Women's Hospital School Of Medicine Zhejiang University is the lead sponsor of 79 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
positive in diagnosis of ABO-HDN
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
positive in diagnosis of ABO-HDN
negative in diagnosis of ABO-HDN
concentration of ETCOc (end tidal carbon monoxide)
ETCOc in ppm
Time frame: through study completion, planned to be 1.5 year
concentration of bilirubin
bilirubin in mg/dl
Time frame: through study completion, planned to be 1.5 year
result of DAT
DAT result of positive or negtive
Time frame: through study completion, planned to be 1.5 year
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Women's Hospital School Of Medicine Zhejiang University